Mesenchymal Stem Cells Market 2020 Trending Technologies, Innovations, New Developments, Key Players And End-Use Industry : Cell Applications Inc….

(March 2021) Polaris Market Research recently released a Mesenchymal Stem CellsMarket report. The report provides the overall scope of the market, including future supply and demand, emerging market trends, high growth opportunities and in-depth analysis of the markets future prospects. The report discusses competitive data analysis of emerging markets and leading market participants. In addition, it provides comprehensive data analysis on risk factors, challenges, and possible new routes in the market.

The research provides a comprehensive knowledge platform for market participants and investors, as well as senior companies and manufacturers active in the global Mesenchymal Stem Cells market. The report includes CAGR, market share, revenue, gross margin, value, volume and other key market data, which can accurately show the growth of the global Mesenchymal Stem Cells market. We also focus on SWOT analysis, BCG matrix, SCOT analysis and PESTLE analysis for the global Mesenchymal Stem Cells market.

Get MoreDetails on this Report, Download Now( Sample PDF) : https://www.polarismarketresearch.com/industry-analysis/mesenchymal-stem-cells-market/request-for-sample

Manufacturers covered in this report are:

Cell Applications, Inc., Cyagen Biosciences Inc. Axol Bioscience Ltd., Cytori Therapeutics Inc., Stem cell technologies Inc., Celprogen, Inc. BrainStorm Cell Therapeutics, Stemedica Cell Technologies, Inc

Competitive Structure and Analysis of the Mesenchymal Stem Cells Market:

1) Constant Growth, Expanding Margins

Some companies have excellent growth records from 2014 to 2020. Some of these companies have achieved tremendous growth in sales and revenue, while net income in the same period has doubled with the growth of performance and gross profit margin. Over the years, the increase in gross profit margin shows that, in addition to the increase in the cost of product sales, the company has a strong pricing power for products.

The Mesenchymal Stem Cells report further performs functional analysis, which contains detailed information about the companys manufacturing base, output, scale, value chain, and product specifications.

2) Devised Growth Plans & Rising Competition?

Mesenchymal Stem Cells market participants have established strategies to provide a large number of new product launches in multiple markets around the world. To confirm the comprehensive practice, some player profiles worth reviewing are Cell Applications, Inc., Cyagen Biosciences Inc. Axol Bioscience Ltd., Cytori Therapeutics Inc., Stem cell technologies Inc., Celprogen, Inc. BrainStorm Cell Therapeutics, Stemedica Cell Technologies, Inc

3) Status Of The Market In TodayS World

Although the market segmentation has made considerable gains, it may not be so encouraging in recent years, but if manufacturers can take plan-driven initiatives earlier, the situation may be better. It is different from the past, but it is estimated that the investment cycle in the United States will continue to evolve, and these companies will face many growth opportunities by 2021. This seems to be good news for today, but it is foreseeable that the leading participants will receive greater Return.

To get Incredible Discounts on this Report, Click Here @ https://www.polarismarketresearch.com/industry-analysis/mesenchymal-stem-cells-market/request-for-discount-pricing

Market Segmentation:

Polaris Market Research has segmented the global mesenchymal stem cells market on the basis of source type, application and region:

Mesenchymal Stem Cells Source Type Outlook (Revenue, USD Million, 2015 2026)

Mesenchymal Stem Cells Application Outlook (Revenue, USD Million, 2015 2026)

Overview of the Regional Outlook of this Market:

The Mesenchymal Stem Cells report provides information about market regions, which are further broken down into subregions and countries. In addition to market share in each country and sub-region, this chapter of this report also contains information about profit opportunities. This chapter of the report mentions the share and market growth rate of each region, country, and sub-region in the estimated time period.

Cumulative Impact of COVID-19:

The Covid-19 (coronavirus) pandemic is affecting societies and overall economies around the world. The impact of this pandemic is increasing and it affects the supply chain. The COVID-19 crisis has created uncertainty in the stock market, supply chains have slowed sharply, business confidence has fallen, and panic among customer groups has increased. The overall impact of the pandemic is affecting production processes in several industries. This report on the Mesenchymal Stem Cells market provides an analysis of the impact of Covid-19 in various business areas and country/regional markets. The report also shows market trends and forecasts for 2027, taking into account the impact of Covid -19.

Major Features of Mesenchymal Stem Cells Market Report:

If You Have Any Query, Ask Our Experts @ https://www.polarismarketresearch.com/industry-analysis/mesenchymal-stem-cells-market/speak-to-analyst

About Polaris market Research

Polaris market Research is a global market research and consulting company. We provide unmatched quality of offerings to our clients present globally. The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across industry verticals.

Contact Us

Corporate Sales, USA

Polaris market Research

Phone: 1-646-568-9980

Email:[emailprotected]

Web:www.polarismarketresearch.com

Read the original here:

Mesenchymal Stem Cells Market 2020 Trending Technologies, Innovations, New Developments, Key Players And End-Use Industry : Cell Applications Inc....

Read more
IMAC Holdings, Inc. Announces Completion of First Cohort of its Phase 1 Clinical Study of Umbilical Cord-Derived Mesenchymal Stem Cells for the…

BRENTWOOD, Tenn, March 01, 2021 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. ( IMAC) (IMAC or the Company), today announces it has completed the first cohort of its Phase 1 clinical trial for its investigational compound utilizing umbilical cord-derived allogenic mesenchymal stem cells for the treatment of bradykinesia due to Parkinsons disease.

The first cohort consists of five patients with bradykinesia due to Parkinsons disease receiving a low dose, intravenous infusion of the stem cell treatment. The cohort was completed on Friday, February 26, 2021. In accordance with the trial protocol, the Company will wait at least 30 days to demonstrate safety of the low dose before initiating the second cohort in which five patients will receive a medium intravenous dose.

About IMACs Phase 1 Clinical Trial

The Phase 1 clinical trial, consisting of a 15-patient dose escalation safety and tolerability study, will be conducted at three of IMACs clinical centers in Chesterfield, Missouri, Paducah, Kentucky, and Brentwood, Tennessee. The trial will be divided into three groups: 1) five patients with bradykinesia due to Parkinsons disease will receive a low dose, intravenous infusion of stem cells, 2) five will receive a medium intravenous dose, 3) and five will receive a high intravenous dose. All groups will be subsequently tracked for 12 months. IMACs medical doctors and physical therapists at the clinical sites have been trained to administer the treatment and manage the therapy. Ricardo Knight, M.D., M.B.A., who is medical director of the Mike Ditka IMAC Regeneration Center, is the trials principal investigator.

The Institute of Regenerative and Cellular Medicine will serve as the trials independent investigational review board, while Regenerative Outcomes provides management of the study. Further details of the trial can be found here.

About Bradykinesia Due to Parkinsons Disease

In addition to unusually slow movements and reflexes, bradykinesia may lead to limited ability to lift arms and legs, reduced facial expressions, rigid muscle tone, a shuffling walk, and difficulty with repetitive motion tasks, self-care, and daily activities. Parkinsons disease is the typical culprit of bradykinesia, and as it progresses through its stages, a persons ability to move and respond declines.

According to Zion Market Research, the global Parkinsons disease therapeutics market was $2.61 billion in 2018 and is expected to grow to $5.28 billion by 2025. The Parkinsons Disease Foundation estimates that nearly 10 million people are suffering from Parkinsons disease, and almost 60,000 new cases are reported annually in the U.S.

About IMAC Holdings, Inc.

IMAC was created in March 2015 to expand on the footprint of the original IMAC Regeneration Center, which opened in Kentucky in August 2000. IMAC Regeneration Centers combine life-science advancements with traditional medical care for movement restricting diseases and conditions. IMAC owns or manages more than 15 outpatient clinics that provide regenerative, orthopedic and minimally invasive procedures and therapies. It has partnered with several active and former professional athletes including Ozzie Smith, David Price, Mike Ditka and Tony Delk. IMACs outpatient medical clinics emphasize treating sports and orthopedic injuries and movement-restricting diseases without surgery or opioids. More information about IMAC Holdings, Inc. is available at http://www.imacregeneration.com.

# # #

Safe Harbor Statement

This press release contains forward-looking statements. These forward-looking statements, and terms such as anticipate, expect, believe, may, will, should or other comparable terms, are based largely on IMAC's expectations and are subject to a number of risks and uncertainties, certain of which are beyond IMAC's control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, risks and uncertainties associated with its ability to raise additional funding, its ability to maintain and grow its business, variability of operating results, its ability to maintain and enhance its brand, its development and introduction of new products and services, the successful integration of acquired companies, technologies and assets, marketing and other business development initiatives, competition in the industry, general government regulation, economic conditions, dependence on key personnel, the ability to attract, hire and retain personnel who possess the skills and experience necessary to meet customers requirements, and its ability to protect its intellectual property. IMAC encourages you to review other factors that may affect its future results in its registration statement and in its other filings with the Securities and Exchange Commission. In light of these risks and uncertainties, there can be no assurance that the forward-looking information contained in this press release will in fact occur.

IMAC Press Contact: Laura Fristoe[emailprotected]

Investor Relations: Bret Shapiro(516) 222-2560[emailprotected]

Read more from the original source:

IMAC Holdings, Inc. Announces Completion of First Cohort of its Phase 1 Clinical Study of Umbilical Cord-Derived Mesenchymal Stem Cells for the...

Read more
Stem cells and COVID-19: are the human amniotic cells a new hope for therapies against the SARS-CoV-2 virus? – DocWire News

This article was originally published here

Stem Cell Res Ther. 2021 Mar 1;12(1):155. doi: 10.1186/s13287-021-02216-w.

ABSTRACT

A new coronavirus respiratory disease (COVID-19) caused by the SARS-CoV-2 virus, surprised the entire world, producing social, economic, and health problems. The COVID-19 triggers a lung infection with a multiple proinflammatory cytokine storm in severe patients. Without effective and safe treatments, COVID-19 has killed thousands of people, becoming a pandemic. Stem cells have been suggested as a therapy for lung-related diseases. In particular, mesenchymal stem cells (MSCs) have been successfully tested in some clinical trials in patients with COVID-19. The encouraging results positioned MSCs as a possible cell therapy for COVID-19. The amniotic membrane from the human placenta at term is a valuable stem cell source, including human amniotic epithelial cells (hAECs) and human mesenchymal stromal cells (hAMSCs). Interestingly, amnion cells have immunoregulatory, regenerative, and anti-inflammatory properties. Moreover, hAECs and hAMSCs have been used both in preclinical studies and in clinical trials against respiratory diseases. They have reduced the inflammatory response and restored the pulmonary tissue architecture in lung injury in vivo models. Here, we review the existing data about the stem cells use for COVID-19 treatment, including the ongoing clinical trials. We also consider the non-cellular therapies that are being applied. Finally, we discuss the human amniotic membrane cells use in patients who suffer from immune/inflammatory lung diseases and hypothesize their possible use as a successful treatment against COVID-19.

PMID:33648582 | DOI:10.1186/s13287-021-02216-w

Go here to see the original:

Stem cells and COVID-19: are the human amniotic cells a new hope for therapies against the SARS-CoV-2 virus? - DocWire News

Read more
Cynata tests wound dressing tech for stem cell therapy delivery – The West Australian

ASX-listed Cynata Therapeutics has signed an MoU with TekCyte Pty Ltd to access its wound dressing technology in the hope of commercialising TekCytes proprietary surface modifications of polymer-coated dressings for the delivery of Cynatas mesenchymal stem cells, or MSC, to wounds.

The Melbourne-based clinical-stage stem cell and regenerative medicine company is specifically looking to use TekCytes technologies in the commercial development of Cynatas MSC product for the treatment of diabetic foot ulcers.

Cynata said its trademarked Cymerus MSCs have already demonstrated promising efficacy in a pre-clinical model of diabetic wounds, often referred to as diabetic ulcers, utilising TekCytes dressing when seeded with MSCs or similar cells.

The company now plans to build on the solid pre-clinical foundation by conducting a clinical trial of its Cymerus MSC product on patients with diabetic foot ulcers using an active dressing supplied by TekCyte.

Cynata expects to start the clinical trial as soon as possible after it completes negotiations with TekCyte on a formal license agreement.

The company says diabetic foot ulcers are a significant medical problem with an estimated market value of nearly US$10 billion based on data sourced from Transparent Market Researchs review of the global diabetic foot ulcers treatment market out to 2027.

In Australia alone, diabetic foot disease results in more than 27,000 hospitalisations, 4,400 amputations and 1,700 deaths annually. Unfortunately, there is also evidence that the burden of this disease is growing year-on-year, and existing treatment options have limited success.

The very encouraging data from the pre-clinical studies at the CTM-CRC with our Cymerus MSC product, especially when compared with other cell products, provides a rational and sound basis for us to proceed with TekCytes patch technology.

Elsewhere in Cynatas labs and clinical trial sites, the company is working to deploy its stem cell technology across a range of ailments, including Osteoarthritis, renal transplantation, idiopathic pulmonary fibrosis and even COVID-19.

Stem cells, most familiar as embryonic stem cells, are special human cells capable of morphing into all other cell varieties from muscles to brain cells.

Whilst stem cell technology has been developing for a decade or two now, it has been routinely based on using hematopoietic stem cells to treat disease. However, a donor can currently transplant these cells only if a perfect match is available.

Instead of the arduous process of undertaking donor match searches, Cynata believes plentiful stem cells can be derived another way. By transforming adult stem cells with a type of genetic reprogramming, the company says it can create pluripotent stem cells that are capable of operating identically to the valuable embryonic cells.

The companys proprietary Cymerus technology uses pluripotent cells combined with a precursor cell called mesenchymoangioblasts, or MCA to fabricate numerous cell therapy products, including mesenchymal stem cells or MSCs.

Importantly, Cynata says it can produce those essential cells at a commercial scale, forgoing the need for multiple donors and conquering the usual supply bottlenecks currently frustrating stem cell therapies and researchers worldwide.

Other candidate diseases facing this potentially boundless technology include asthma, heart attack, sepsis, acute respiratory distress syndrome, or ARDS and cytokine release syndrome.

Plans are already well advanced for further clinical trials of the fascinating Cymerus MSC products in Graft-versus-host Disease, or GvHD through licensee Fujifilm.

GvHD is an all-too-common consequence of traditional stem cell therapies and is one of the earliest ailments to be attacked by Cynatas technology.

Cynata looks to be hurtling down a path to turn science fiction into reality by developing a wound patch that can effectively regenerate the bodys own cells a bit more than just a band-aid approach, perhaps?

Is your ASX-listed company doing something interesting? Contact: matt.birney@wanews.com.au

Follow this link:

Cynata tests wound dressing tech for stem cell therapy delivery - The West Australian

Read more
Human Mesenchymal Stem Cells (hMSC) Market Size 2021 | Global Trends, Business Overview, Challenges, Opportunities and Forecast to 2027 The Bisouv…

Request Download Sample Ask For Discount Company Profile

New Jersey, United States,-The Human Mesenchymal Stem Cells (hMSC) Market report provides in-depth knowledge and insights into the Human Mesenchymal Stem Cells (hMSC) market in terms of market size, market share, factors influencing growth, opportunities, and current and emerging trends. The report has the updated and latest information on the Human Mesenchymal Stem Cells (hMSC) market that has been further validated and verified by industry experts and professionals. The Human Mesenchymal Stem Cells (hMSC) market report provides historical, current, and forecast estimates of sales generation and profit for each segment and sub-segment of the Human Mesenchymal Stem Cells (hMSC) market in every key region around the world. The report also highlights the emerging growth opportunities in the business that are designed to support market growth.

The latest report is the latest study to offer 360 coverage of the Human Mesenchymal Stem Cells (hMSC) industry, which is facing the worst negative economic impact of the COVID-19 outbreak since the beginning of this year.

The report covers the following key players in the Human Mesenchymal Stem Cells (hMSC) Market:

PromoCell ThermoFisher KURABO Lifeline Cell Technology Merck

Segmentation of Human Mesenchymal Stem Cells (hMSC) Market:

The report provides an in-depth analysis of various market segments based on the product line, applications, major regions, and key companies in the industry. In addition, the report has a single section that provides a detailed analysis of the manufacturing process and includes information gathered from primary and secondary data collection sources. The main source for data collection is interviews with industry experts who provide accurate information about the future market scenario.

By the product type, the market is primarily split into:

Umbilical Cord Matrix hMSC Bone Marrow hMSC Adipose Tissue hMSC Other

By the application, this report covers the following segments:

Medical Application Research Other Applications

Human Mesenchymal Stem Cells (hMSC) Market Report Scope

Human Mesenchymal Stem Cells (hMSC) Geographic Market Analysis:

The latest business intelligence report analyzes the Human Mesenchymal Stem Cells (hMSC) market in terms of market reach and customer base in key geographic market regions. The Human Mesenchymal Stem Cells (hMSC) market can be geographically divided into North America, Asia Pacific, Europe, Latin America, the Middle East, and Africa. This section of the report provides an accurate assessment of the Human Mesenchymal Stem Cells (hMSC) market presence in the major regions. It defines the market share, market size, sales, distribution network and distribution channels for each regional segment.

Key Points of theGeographical Analysis:

** Data and information on consumption in each region** The estimated increase in consumption rate** Proposed growth in market share for each region** Geographic contribution to market income** Expected growth rates of the regional markets

Key Highlights of the Human Mesenchymal Stem Cells (hMSC)Market Report:

** Analysis of location factors** Raw material procurement strategy** Product mix matrix** Analysis to optimize the supply chain** Patent analysis** R&D analysis** Analysis of the carbon footprint** Price volatility before commodities** Benefit and cost analysis** Assessment and forecast of regional demand** Competitive analysis** Supplier management** Mergers and acquisitions** Technological advances

Visualize Human Mesenchymal Stem Cells (hMSC) Market using Verified Market Intelligence:-

Verified Market Intelligence is our BI-enabled platform for narrative storytelling of this market. VMI offers in-depth forecasted trends and accurate Insights on over 20,000+ emerging & niche markets, helping you make critical revenue-impacting decisions for a brilliant future.

VMI provides a holistic overview and global competitive landscape with respect to Region, Country, and Segment, and Key players of your market. Present your Market Report & findings with an inbuilt presentation feature saving over 70% of your time and resources for Investor, Sales & Marketing, R&D, and Product Development pitches. VMI enables data delivery In Excel and Interactive PDF formats with over 15+ Key Market Indicators for your market.

About Us: Verified Market Reports

Verified Market Reports is a leading Global Research and Consulting firm servicing over 5000+ global clients. We provide advanced analytical research solutions while offering information-enriched research studies.

We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyze data on more than 25,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.

Our research spans over a multitude of industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverages etc. Having serviced many Fortune 2000 organizations, we bring a rich and reliable experience that covers all kinds of research needs.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (753)-715-0008APAC: +61 (488)-85-9400US Toll-Free: +1 (800)-782-1768

Email: [emailprotected]

Website: https://www.verifiedmarketreports.com/

Originally posted here:

Human Mesenchymal Stem Cells (hMSC) Market Size 2021 | Global Trends, Business Overview, Challenges, Opportunities and Forecast to 2027 The Bisouv...

Read more
Mesenchymal Stem Cells Market Growth, Recent Trends by Regions, Type, Application and Geographical Analysis to 2025 The Bisouv Network – The Bisouv…

The report offers a brilliant, complete research study of the global Mesenchymal Stem Cells market. It takes into account market competition, segmentation, geographical expansion, regional growth, market size, and other factors that are important from a market experts point of view. Market players and stakeholders can use the information and data provided in the report to get sound understanding of the global Mesenchymal Stem Cells Market and the industry as well. Market figures such as BPS, CAGR, market share, revenue, production, consumption, gross margin, and price are accurately calculated with the use of advanced and reliable tools and sources. All of the leading companies included in the report are profiled, keeping in view their recent developments, business strategies, market growth, market share, and other key factors.

Request sample copy of this report at https://www.qualitymarketreports.com/sample-request/1871

The regional study offered in the report helps to become familiar with important market opportunities available in different parts of the world. The competitive analysis section of the report gives critical details about market leaders and other prominent players of the global Mesenchymal Stem Cells market. The report also provides Mesenchymal Stem Cells market structure analysis, cost structure analysis, absolute dollar opportunity analysis, manufacturing cost analysis, and other key types of analysis. The market dynamics section of the report sheds light on market drivers, restraints, trends, opportunities, challenges, and other growth influence factors.

Key Companies

LonzaThermo FisherBio-TechneMiltenyi BiotecPromoCell GmbHIrvine ScientificAxol BioscienceSTEMCELL TechnologiesBiological IndustriesMesoblast

Critical questions of Mesenchymal Stem Cells Market addressed by the report:

What are the key market drivers and restraints?

What will be the market size until the end of the forecast period?

Which segment is expected to take the lions share?

Which region will lead the global Mesenchymal Stem Cells market in terms of growth?

What will be the key strategies adopted by market leaders in future?

What are the upcoming applications?

How will the global Mesenchymal Stem Cells market develop in the mid to long term?

Inquire for discount offer at https://www.qualitymarketreports.com/discount-request/1871

Research Methodology of Mesenchymal Stem Cells Market:

Our research methodology comprises three steps. The first step focuses on exhaustive primary and secondary researches, where we collect information and data on the global Mesenchymal Stem Cells market, the parent market, and the peer market. We then connect with industry experts across the value chain to validate our market sizing estimations, findings, and assumptions. The next step involves estimating the complete market size with the help of bottom-up and top-down approaches. The last step is about the estimation of the market size of all of the segments and sub-segments using data triangulation and market breakup procedures.

Complete Report is Available at https://www.qualitymarketreports.com/report/1871-2015-2025-global-mesenchymal-stem-cells-market-research-by-type-end-use-and-region-covid-19-version.html

Primary Sources:

Our primary sources include but are not limited to key executives from important companies and organizations and top-level executives such as innovation and technology directors, marketing directors, VPs, and CEOs. We collect information and data from the supply as well as demand side of the global Mesenchymal Stem Cells market.

Secondary Sources:

As part of our secondary research, we gather key insights and information from company investor reports, annual earnings reports, press releases, government and company databases, directories, articles from recognized authors, certified journals and publications, white papers, investor presentation reports, and various other sources.

Table of Contents:

Report Overview:It includes study scope, players covered, key Mesenchymal Stem Cells market segments, market analysis by application, market analysis by type, and other chapters that give an overview of the research study.

Executive Summary:This section of the report gives information about key industry trends and shares market size analysis by region and analysis of global market size. Under market size analysis by region, analysis of market share and growth rate by region is provided.

Profiles of International Players:Here, key players are studied on the basis of gross margin, price, revenue, corporate sales, and production. This section gives a business overview of the players and shares their important company details.

Regional Study:All of the regions and countries analyzed in the report are studied on the basis of market size by application, market size by product, key players, and market forecast.

Key Players:This part of the report discusses about expansion plans of companies, key mergers and acquisitions, funding and investment analysis, company establishment dates, revenues of manufacturers, and their areas served and manufacturing bases.

Breakdown Mesenchymal Stem Cells Market by Product and Application: The review period considered here is 2013-2025.

About Us:

QualityMarketReports is a market research firm dealing in resale of market research reports. We have large database of market research reports which are based on complete survey including different categories and sub categories. All are available under one roof to serve you in a better way in minimum time and at affordable cost.

Our market reports are used by the clients of different industries across the world to fulfill their market research requirement to establish their business successfully.

We provide 24/7 support regarding client needs of market research survey. We are always bound to serve you in a better way regarding marketing needs.

Contact Us:

[emailprotected]

More:

Mesenchymal Stem Cells Market Growth, Recent Trends by Regions, Type, Application and Geographical Analysis to 2025 The Bisouv Network - The Bisouv...

Read more
Mesenchymal Stromal Cell-Based Therapy: A Promising Approach for Severe COVID-19 – DocWire News

This article was originally published here

Cell Transplant. 2021 Jan-Dec;30:963689721995455. doi: 10.1177/0963689721995455.

ABSTRACT

During the outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), many critically ill patients died of severe pneumonia, acute respiratory distress syndrome (ARDS), or multiple organ dysfunction syndrome. To date, no specific treatments have been proven to be effective for coronavirus disease 2019 (COVID-19). In the animal models and clinical applications, mesenchymal stromal/stem cells (MSCs) have been shown safety and efficacy for the treatment of respiratory virus infection through their abilities of differentiation and immunomodulation. Besides, possessing several advantages of MSC-derived extracellular vesicles (EVs) over MSCs, EV-based therapy also holds potential therapeutic effects in respiratory virus infection. In this review, we summarized the basic characteristics and mechanisms of COVID-19 and MSCs, outlined some preclinical and clinical studies of MSCs or MSC-EVs for respiratory virus infection such as influenza virus and SARS-CoV-2, shed light on the common problems that we should overcome to translate MSC therapy into clinical application, and discussed some safe issues related to the use of MSCs.

PMID:33650894 | DOI:10.1177/0963689721995455

Follow this link:

Mesenchymal Stromal Cell-Based Therapy: A Promising Approach for Severe COVID-19 - DocWire News

Read more
Mesenchymal Stem Cells Market Size 2021 | Global Trends, Business Overview, Challenges, Opportunities and Forecast to 2027 The Bisouv Network – The…

Request Download Sample Ask For Discount Company Profile

New Jersey, United States,-The Mesenchymal Stem Cells Market report provides in-depth knowledge and insights into the Mesenchymal Stem Cells market in terms of market size, market share, factors influencing growth, opportunities, and current and emerging trends. The report has the updated and latest information on the Mesenchymal Stem Cells market that has been further validated and verified by industry experts and professionals. The Mesenchymal Stem Cells market report provides historical, current, and forecast estimates of sales generation and profit for each segment and sub-segment of the Mesenchymal Stem Cells market in every key region around the world. The report also highlights the emerging growth opportunities in the business that are designed to support market growth.

The latest report is the latest study to offer 360 coverage of the Mesenchymal Stem Cells industry, which is facing the worst negative economic impact of the COVID-19 outbreak since the beginning of this year.

The report covers the following key players in the Mesenchymal Stem Cells Market:

Lonza Thermo Fisher Bio-Techne ATCC MilliporeSigma PromoCell GmbH Genlantis Celprogen Cell Applications Cyagen Biosciences

Segmentation of Mesenchymal Stem Cells Market:

The report provides an in-depth analysis of various market segments based on the product line, applications, major regions, and key companies in the industry. In addition, the report has a single section that provides a detailed analysis of the manufacturing process and includes information gathered from primary and secondary data collection sources. The main source for data collection is interviews with industry experts who provide accurate information about the future market scenario.

By the product type, the market is primarily split into:

Human MSC Mouse MSC Rat MSC Other

By the application, this report covers the following segments:

Research Institute Hospital Others

Mesenchymal Stem Cells Market Report Scope

Mesenchymal Stem Cells Geographic Market Analysis:

The latest business intelligence report analyzes the Mesenchymal Stem Cells market in terms of market reach and customer base in key geographic market regions. The Mesenchymal Stem Cells market can be geographically divided into North America, Asia Pacific, Europe, Latin America, the Middle East, and Africa. This section of the report provides an accurate assessment of the Mesenchymal Stem Cells market presence in the major regions. It defines the market share, market size, sales, distribution network and distribution channels for each regional segment.

Key Points of theGeographical Analysis:

** Data and information on consumption in each region** The estimated increase in consumption rate** Proposed growth in market share for each region** Geographic contribution to market income** Expected growth rates of the regional markets

Key Highlights of the Mesenchymal Stem CellsMarket Report:

** Analysis of location factors** Raw material procurement strategy** Product mix matrix** Analysis to optimize the supply chain** Patent analysis** R&D analysis** Analysis of the carbon footprint** Price volatility before commodities** Benefit and cost analysis** Assessment and forecast of regional demand** Competitive analysis** Supplier management** Mergers and acquisitions** Technological advances

Visualize Mesenchymal Stem Cells Market using Verified Market Intelligence:-

Verified Market Intelligence is our BI-enabled platform for narrative storytelling of this market. VMI offers in-depth forecasted trends and accurate Insights on over 20,000+ emerging & niche markets, helping you make critical revenue-impacting decisions for a brilliant future.

VMI provides a holistic overview and global competitive landscape with respect to Region, Country, and Segment, and Key players of your market. Present your Market Report & findings with an inbuilt presentation feature saving over 70% of your time and resources for Investor, Sales & Marketing, R&D, and Product Development pitches. VMI enables data delivery In Excel and Interactive PDF formats with over 15+ Key Market Indicators for your market.

About Us: Verified Market Reports

Verified Market Reports is a leading Global Research and Consulting firm servicing over 5000+ global clients. We provide advanced analytical research solutions while offering information-enriched research studies.

We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyze data on more than 25,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.

Our research spans over a multitude of industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverages etc. Having serviced many Fortune 2000 organizations, we bring a rich and reliable experience that covers all kinds of research needs.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (753)-715-0008APAC: +61 (488)-85-9400US Toll-Free: +1 (800)-782-1768

Email: [emailprotected]

Website: https://www.verifiedmarketreports.com/

Read the original:

Mesenchymal Stem Cells Market Size 2021 | Global Trends, Business Overview, Challenges, Opportunities and Forecast to 2027 The Bisouv Network - The...

Read more
Exercise to survive a heart attack . . . and other stories – The BMJ

Death following myocardial infarction

Combining data from 10 European longitudinal studies identified nearly 30000 people who experienced a heart attack. Around 5000 (18%) died within 28 days and, of these, 3000 (62%) died instantly. Risk of sudden death was influenced by past levels of physical activity. People who, at the time of recruitment, reported moderate or high levels of leisure time exercise reduced their risk by 33% and 45%, respectively (Eur J Prevent Cardiol doi:10.1093/eurjpc/zwaa146).

A few years ago, a Cochrane review reckoned that omega-3 fish oils had no worthwhile cardiovascular protective effect (Cochrane Database Syst Rev doi:10.1002/14651858.CD003177.pub3/full

Continued here:

Exercise to survive a heart attack . . . and other stories - The BMJ

Read more
Mesenchymal Stem Cell Derived-Exosomes as Effective Factors in Reducing Cytokine Storm Symptoms of COVID-19 – DocWire News

This article was originally published here

Protein Pept Lett. 2021 Feb 22. doi: 10.2174/0929866528666210222150347. Online ahead of print.

ABSTRACT

Given that conventional therapies are ineffective for COVID-19, obtained exosomes from stem cells have been proposed as a sustainable and effective treatment. Exosomes are subsets with lengths between 30 and 100 nanometers, and they can be secreted by different cells. Exosomes are containing different types of miRNAs, mRNAs, and different proteins. The role of immune system modulation of exosomes of mesenchymal stem cells has been studied and confirmed in more than one study. Exosome miRNAs detect and reduce cytokines that cause cytokine storms such as IL-7, IL-2, IL-6, etc. These miRNAs include miR-21, miR-24, miR-124, miR-145, etc. The risks associated with treatment with exosomes from different cells are relatively small compared to other treatments because transplanted cells do not stimulate the host immune system and also has reduced infection transmission. Due to the ineffectiveness of existing drugs in reducing inflammation and preventing cytokine storms, the use of immune-boosting systems may be suggested as another way to control cytokine storm.

PMID:33618635 | DOI:10.2174/0929866528666210222150347

Read this article:

Mesenchymal Stem Cell Derived-Exosomes as Effective Factors in Reducing Cytokine Storm Symptoms of COVID-19 - DocWire News

Read more